Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Aditya Bardia, M.B.,B.S.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Vidula N, Dubash TD, Lawrence MS, Simoneau A, Niemierko A, Blouch EL, Nagy RJ, Roh W, Chirn B, Reeves B, Malvarosa G, Lennerz JK, Isakoff SJ, Juric D, Micalizzi DS, Wander SA, Spring LM, Moy B, Shannon KM, Younger J, Lanman RB, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A. Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer. Clin Cancer Res. 2020 Jun 22. PMID: 32571788.
    Citations:    
  2. Ho AY, Wright JL, Blitzblau RC, Mutter RW, Duda DG, Norton L, Bardia A, Spring L, Isakoff SJ, Chen JH, Grassberger C, Bellon JR, Beriwal S, Khan AJ, Speers C, Dunn SA, Thompson A, Santa-Maria CA, Krop IE, Mittendorf E, King TA, Gupta GP. Optimizing Radiotherapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2020 May 14. PMID: 32417409.
    Citations:    
  3. Nagayama A, Vidula N, Ellisen L, Bardia A. Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol. 2020; 12:1758835920915980. PMID: 32426047.
    Citations:    
  4. McCarthy AM, Kumar NP, He W, Regan S, Welch M, Moy B, Iafrate AJ, Chan AT, Bardia A, Armstrong K. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. BMC Cancer. 2020 Apr 23; 20(1):347. PMID: 32326897.
    Citations:    
  5. Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q, Delaney RJ, Hafeez A, André F, Schmid P. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. Future Oncol. 2020 Apr; 16(12):705-715. PMID: 32223649.
    Citations:    
  6. Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020 03 07; 395(10226):817-827. PMID: 32145796.
    Citations:    
  7. Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 Jun 15; 26(12):2838-2848. PMID: 32046998.
    Citations:    
  8. Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol. 2020 04; 38(4):420-425. PMID: 32042168.
    Citations:    
  9. Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 Jun 01; 26(11):2546-2555. PMID: 32034076.
    Citations:    
  10. Ebright RY, Lee S, Wittner BS, Niederhoffer KL, Nicholson BT, Bardia A, Truesdell S, Wiley DF, Wesley B, Li S, Mai A, Aceto N, Vincent-Jordan N, Szabolcs A, Chirn B, Kreuzer J, Comaills V, Kalinich M, Haas W, Ting DT, Toner M, Vasudevan S, Haber DA, Maheswaran S, Micalizzi DS. Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. Science. 2020 03 27; 367(6485):1468-1473. PMID: 32029688.
    Citations:    
  11. Klotz R, Thomas A, Teng T, Han SM, Iriondo O, Li L, Restrepo-Vassalli S, Wang A, Izadian N, MacKay M, Moon BS, Liu KJ, Ganesan SK, Lee G, Kang DS, Walmsley CS, Pinto C, Press MF, Lu W, Lu J, Juric D, Bardia A, Hicks J, Salhia B, Attenello F, Smith AD, Yu M. Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers. Cancer Discov. 2020 Jan; 10(1):86-103. PMID: 31601552.
    Citations:    
  12. Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, Huynh T, Healy C, Peterson R, Yanase S, Jakubik CT, Henderson LE, Damon LJ, Timonina D, Sanidas I, Pinto CJ, Mino-Kenudson M, Stone JR, Dyson NJ, Ellisen LW, Bardia A, Ebi H, Benes CH, Engelman JA, Juric D. PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Ka Inhibitors in Breast Cancer. Cancer Discov. 2020 Jan; 10(1):72-85. PMID: 31594766.
    Citations:    
  13. Peppercorn J, Campbell E, Isakoff S, Horick NK, Rabin J, Quain K, Sequist LV, Bardia A, Collyar D, Hlubocky F, Mathews D. Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. Oncologist. 2020 01; 25(1):78-86. PMID: 31492767.
    Citations:    
  14. Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG. EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Future Oncol. 2019 Oct; 15(28):3209-3218. PMID: 31426673.
    Citations:    
  15. Bardia A, Gounder M, Rodon J, Janku F, Lolkema MP, Stephenson JJ, Bedard PL, Schuler M, Sessa C, LoRusso P, Thomas M, Maacke H, Evans H, Sun Y, Tan DSW. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. Oncologist. 2020 01; 25(1):e160-e169. PMID: 31395751.
    Citations:    
  16. Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2019 09; 20(9):1226-1238. PMID: 31402321.
    Citations:    
  17. Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. Clin Cancer Res. 2019 11 01; 25(21):6443-6451. PMID: 31371343.
    Citations:    
  18. Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A. Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol. 2019; 3:18. PMID: 31341951.
    Citations:    
  19. Bardia A, Mayer IA, Kalinsky K. Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply. N Engl J Med. 2019 06 13; 380(24):2382. PMID: 31189049.
    Citations:    
  20. Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 07 25; 381(4):307-316. PMID: 31166679.
    Citations:    
  21. Goel S, Pernas S, Tan-Wasielewski Z, Barry WT, Bardia A, Rees R, Andrews C, Tahara RK, Trippa L, Mayer EL, Winer EP, Spring LM, Tolaney SM. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clin Breast Cancer. 2019 12; 19(6):399-404. PMID: 31235441.
    Citations:    
  22. Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy. Breast Cancer Res Treat. 2019 Aug; 176(3):617-624. PMID: 31079282.
    Citations:    
  23. Wander SA, Spring LM, Bardia A. Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer. Lancet Oncol. 2019 06; 20(6):746-748. PMID: 31036469.
    Citations:    
  24. Cheng J, Cao Y, MacLeay A, Lennerz JK, Baig A, Frazier RP, Lee J, Hu K, Pacula M, Meneses E, Robinson H, Batten JM, Brastianos PK, Heist RS, Bardia A, Le LP, Iafrate AJ. Clinical Validation of a Cell-Free DNA Gene Panel. J Mol Diagn. 2019 07; 21(4):632-645. PMID: 31026600.
    Citations:    
  25. Daniell KM, Bardia A, Sun F, Roberts SA, Brunelle CL, Gillespie TC, Sayegh HE, Naoum GE, Juric D, Isakoff SJ, Fitzgerald DM, Taghian AG. Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(3):649-658. PMID: 30919166.
    Citations:    
  26. Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 2019 03 26; 10(1):1373. PMID: 30914635.
    Citations:    
  27. Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Curr Oncol Rep. 2019 02 26; 21(3):25. PMID: 30806829.
    Citations:    
  28. Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019 02 21; 380(8):741-751. PMID: 30786188.
    Citations:    
  29. Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clin Cancer Res. 2019 Feb 15; 25(4):1435. PMID: 30770494.
    Citations:    
  30. Keklikoglou I, Cianciaruso C, Güç E, Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonnier A, Ferraro GB, Baer C, Cassará A, Guichard A, Iruela-Arispe ML, Lewis CE, Coussens LM, Bardia A, Jain RK, Pollard JW, De Palma M. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol. 2019 02; 21(2):190-202. PMID: 30598531.
    Citations:    Fields:    
  31. Zangardi ML, Spring LM, Nagayama A, Bardia A. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy? Expert Opin Investig Drugs. 2019 Feb; 28(2):107-112. PMID: 30507322.
    Citations:    Fields:    Translation:Humans
  32. Bardia A, Hovnanian MD, Brachtel EF, Nardi V. Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. N Engl J Med. 2018 Nov 15; 379(20):1946-1953. PMID: 30428289.
    Citations:    Fields:    Translation:Humans
  33. Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol. 2018 Oct 19; JCO1800328. PMID: 30339520.
    Citations:    
  34. Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB. Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. J Clin Oncol. 2018 Sep 20; JCO2017748392. PMID: 30235087.
    Citations:    Fields:    
  35. Princic N, Aizer A, Tang DH, Smith DM, Johnson W, Bardia A. Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer. Curr Med Res Opin. 2019 01; 35(1):73-80. PMID: 30175631.
    Citations:    Fields:    
  36. Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A. Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Res Treat. 2018 Dec; 172(3):733-740. PMID: 30220055.
    Citations:    Fields:    
  37. Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S. A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discov. 2018 10; 8(10):1286-1299. PMID: 30104333.
    Citations:    Fields:    
  38. Bardia A, Hurvitz S. Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances. Clin Cancer Res. 2018 11 01; 24(21):5206-5218. PMID: 29884743.
    Citations:    Fields:    
  39. Abraham E, Post K, Spring L, Malvarosa G, Tripp E, Peppercorn JM, Bardia A, Habin K. Research Biopsies: An Integrative Review of the Experiences of Patients With Cancer. Clin J Oncol Nurs. 2018 06 01; 22(3):E71-E77. PMID: 29781452.
    Citations:    Fields:    
  40. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 07; 19(7):904-915. PMID: 29804902.
    Citations: 3     Fields:    
  41. Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. Breast Cancer Res Treat. 2018 Aug; 171(1):121-129. PMID: 29752687.
    Citations:    Fields:    
  42. Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA. Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. Breast Cancer Res Treat. 2018 Aug; 171(1):111-120. PMID: 29744674.
    Citations:    Fields:    
  43. Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018; 4:10. PMID: 29761158.
    Citations: 2     
  44. Spring L, Bardia A. Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer. Clin Cancer Res. 2018 07 01; 24(13):2981-2983. PMID: 29685881.
    Citations:    Fields:    
  45. Aceto N, Bardia A, Wittner BS, Donaldson MC, O'Keefe R, Engstrom A, Bersani F, Zheng Y, Comaills V, Niederhoffer K, Zhu H, Mackenzie O, Shioda T, Sgroi D, Kapur R, Ting DT, Moy B, Ramaswamy S, Toner M, Haber DA, Maheswaran S. AR Expression in Breast Cancer CTCs Associates with Bone Metastases. Mol Cancer Res. 2018 04; 16(4):720-727. PMID: 29453314.
    Citations: 3     Fields:    
  46. Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Bese N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW. Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. Cancer Discov. 2018 03; 8(3):336-353. PMID: 29242214.
    Citations:    Fields:    
  47. Nagayama A, Ellisen LW, Chabner B, Bardia A. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Target Oncol. 2017 Dec; 12(6):719-739. PMID: 29116596.
    Citations: 2     Fields:    Translation:Humans
  48. Vidula N, Bardia A. Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology. Oncotarget. 2017 Dec 05; 8(63):106167-106168. PMID: 29290935.
    Citations: 1     Fields:    
  49. Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. J Natl Compr Canc Netw. 2017 10; 15(10):1216-1223. PMID: 28982747.
    Citations:    Fields:    Translation:Humans
  50. Zangardi ML, Spring LM, Blouin GC, Bardia A. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Expert Rev Clin Pharmacol. 2017 Nov; 10(11):1169-1176. PMID: 28875723.
    Citations: 1     Fields:    Translation:Humans
  51. Tripathy D, Bardia A, Sellers WR. Mechanism of Action and Clinical Impact of Ribociclib-Response. Clin Cancer Res. 2017 09 15; 23(18):5658. PMID: 28916619.
    Citations:    Fields:    
  52. Kabraji S, Solé X, Huang Y, Bango C, Bowden M, Bardia A, Sgroi D, Loda M, Ramaswamy S. AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer. Breast Cancer Res. 2017 Aug 01; 19(1):88. PMID: 28764807.
    Citations:    Fields:    Translation:Humans
  53. Spring LM, Zangardi ML, Moy B, Bardia A. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist. 2017 09; 22(9):1039-1048. PMID: 28706010.
    Citations: 2     Fields:    Translation:Humans
  54. Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct 01; 123(19):3843-3854. PMID: 28558150.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  55. Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017 Aug 20; 35(24):2790-2797. PMID: 28548889.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  56. Bardia A. Antibody-drug conjugates in breast cancer. Clin Adv Hematol Oncol. 2017 Apr; 15(4):251-254. PMID: 28591100.
    Citations:    Fields:    Translation:Humans
  57. Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. Clin Cancer Res. 2017 07 01; 23(13):3251-3262. PMID: 28351928.
    Citations: 7     Fields:    Translation:HumansCells
  58. Spring L, Bardia A. SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis? Lancet Oncol. 2017 05; 18(5):564-565. PMID: 28314690.
    Citations:    Fields:    Translation:Humans
  59. Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2017 Jul 01; 35(19):2141-2148. PMID: 28291390.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  60. Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clin Cancer Res. 2017 Aug 01; 23(15):4035-4045. PMID: 28270498.
    Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
  61. Sajjadi AY, Isakoff SJ, Deng B, Singh B, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Carp SA. Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI). Biomed Opt Express. 2017 Feb 01; 8(2):555-569. PMID: 28270967.
    Citations: 3     
  62. Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clin Cancer Res. 2017 Jun 15; 23(12):3053-3060. PMID: 28011460.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  63. Yala A, Barzilay R, Salama L, Griffin M, Sollender G, Bardia A, Lehman C, Buckley JM, Coopey SB, Polubriaginof F, Garber JE, Smith BL, Gadd MA, Specht MC, Gudewicz TM, Guidi AJ, Taghian A, Hughes KS. Using machine learning to parse breast pathology reports. Breast Cancer Res Treat. 2017 01; 161(2):203-211. PMID: 27826755.
    Citations: 3     Fields:    Translation:Humans
  64. Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1477-1486. PMID: 27367583.
    Citations: 7     Fields:    Translation:Humans
  65. Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, Yu M, Sundaresan TK, Licausi JA, Desai R, O'Keefe RM, Ebright RY, Boukhali M, Sil S, Onozato ML, Iafrate AJ, Kapur R, Sgroi D, Ting DT, Toner M, Ramaswamy S, Haas W, Maheswaran S, Haber DA. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. 2016 09 01; 537(7618):102-106. PMID: 27556950.
    Citations: 32     Fields:    Translation:HumansCells
  66. Bardia A, Iafrate JA, Sundaresan T, Younger J, Nardi V. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital. Oncologist. 2016 09; 21(9):1035-40. PMID: 27551012.
    Citations: 5     Fields:    Translation:HumansCells
  67. Spring L, Bardia A, Modi S. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discov Med. 2016 Jan; 21(113):65-74. PMID: 26896604.
    Citations: 7     Fields:    Translation:HumansCells
  68. Bardia A, Keenan TE, Ebbert JO, Lazovich D, Wang AH, Vierkant RA, Olson JE, Vachon CM, Limburg PJ, Anderson KE, Cerhan JR. Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. Mayo Clin Proc. 2016 Jan; 91(1):71-80. PMID: 26678006.
    Citations: 5     Fields:    Translation:Humans
  69. Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, Isakoff S, Ellisen LW, Bardia A. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. J Clin Oncol. 2015 Nov 01; 33(31):3621-7. PMID: 26371147.
    Citations: 28     Fields:    Translation:Humans
  70. Gupta A, Mutebi M, Bardia A. Gene-Expression-Based Predictors for Breast Cancer. Ann Surg Oncol. 2015 Oct; 22(11):3418-32. PMID: 26215189.
    Citations: 2     Fields:    Translation:Humans
  71. Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, Engstrom A, Zhu H, Sundaresan TK, Miyamoto DT, Luo X, Bardia A, Wittner BS, Ramaswamy S, Shioda T, Ting DT, Stott SL, Kapur R, Maheswaran S, Haber DA, Toner M. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015 Jul; 12(7):685-91. PMID: 25984697.
    Citations: 72     Fields:    Translation:HumansCells
  72. Reátegui E, Aceto N, Lim EJ, Sullivan JP, Jensen AE, Zeinali M, Martel JM, Aranyosi AJ, Li W, Castleberry S, Bardia A, Sequist LV, Haber DA, Maheswaran S, Hammond PT, Toner M, Stott SL. Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells. Adv Mater. 2015 Mar 04; 27(9):1593-9. PMID: 25640006.
    Citations: 19     Fields:    Translation:HumansCells
  73. Sarangi S, Mosulpuria K, Higgins MJ, Bardia A. The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: from Enumeration to Molecular Characterization. Curr Breast Cancer Rep. 2014 Sep; 6(3):146-153. PMID: 25431637.
    Citations: 1     
  74. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, Shioda T, Ramaswamy S, Ting DT, Lin CP, Toner M, Haber DA, Maheswaran S. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014 Aug 28; 158(5):1110-1122. PMID: 25171411.
    Citations: 292     Fields:    Translation:HumansAnimalsCells
  75. Bardia A, Haber DA. Solidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer? J Clin Oncol. 2014 Nov 01; 32(31):3470-1. PMID: 25024075.
    Citations: 3     Fields:    Translation:HumansCells
  76. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R, Shioda T, Ting DT, Ramaswamy S, Getz G, Iafrate AJ, Benes C, Toner M, Maheswaran S, Haber DA. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014 Jul 11; 345(6193):216-20. PMID: 25013076.
    Citations: 164     Fields:    Translation:HumansAnimalsCells
  77. Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A, Perry A, Burke M, Silver R, Matulis CR, Straley KS, Yen KE, Agresta S, Kim H, Schenkein DP, Borger DR. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. Oncologist. 2014 Jun; 19(6):602-7. PMID: 24760710.
    Citations: 16     Fields:    Translation:Humans
  78. Reynolds K, Sarangi S, Bardia A, Dizon DS. Precision medicine and personalized breast cancer: combination pertuzumab therapy. Pharmgenomics Pers Med. 2014; 7:95-105. PMID: 24715764.
    Citations:    
  79. Bao T, Cai L, Snyder C, Betts K, Tarpinian K, Gould J, Jeter S, Medeiros M, Chumsri S, Bardia A, Tan M, Singh H, Tkaczuk KH, Stearns V. Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer. 2014 Feb 01; 120(3):381-9. PMID: 24375332.
    Citations: 18     Fields:    Translation:Humans
  80. Bardia A, Baselga J. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res. 2013 Dec 01; 19(23):6360-70. PMID: 24298066.
    Citations: 20     Fields:    Translation:Humans
  81. Carp SA, Sajjadi AY, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Isakoff SJ. Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system. Biomed Opt Express. 2013; 4(12):2911-24. PMID: 24409390.
    Citations: 6     
  82. Cheng X, Bhatia A, Specht MC, Smith BL, Moy B, Bardia A. Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer. J Clin Oncol. 2013 Sep 10; 31(26_suppl):147. PMID: 28136533.
    Citations:    
  83. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner M. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013 Apr 03; 5(179):179ra47. PMID: 23552373.
    Citations: 220     Fields:    Translation:HumansCells
  84. Bardia A, Blackford AL, Lin J, Armstrong AJ, King S, Rudek MA, Yegnasubramanian ST, Carducci MA. A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa). J Clin Oncol. 2013 Feb 20; 31(6_suppl):219. PMID: 28137035.
    Citations:    
  85. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013 Feb 01; 339(6119):580-4. PMID: 23372014.
    Citations: 541     Fields:    Translation:HumansAnimalsCells
  86. Singla A, Kumar G, Bardia A. Personalizing cardiovascular disease prevention among breast cancer survivors. Curr Opin Cardiol. 2012 Sep; 27(5):515-24. PMID: 22874128.
    Citations: 4     Fields:    Translation:HumansPHPublic Health
  87. Connolly RM, Bardia A. Trastuzumab for small HER-2+ breast cancer: small tumor, big decision. Oncologist. 2012; 17(4):508-11. PMID: 22491004.
    Citations: 1     Fields:    Translation:Humans
  88. Connolly RM, Bardia A. In reply. Oncologist. 2012; 17(10):e34. PMID: 23104174.
    Citations:    
  89. Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, Hayes DF, Hayden J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, Ouyang P, Wolff AC, Blumenthal RS, Ashen MD, Stearns V. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat. 2012 Feb; 131(3):907-14. PMID: 22042368.
    Citations: 13     Fields:    Translation:Humans
  90. Jones JM, Qin R, Bardia A, Linquist B, Wolf S, Loprinzi CL. Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Palliat Med. 2011 Jul; 14(7):810-4. PMID: 21554125.
    Citations: 7     Fields:    Translation:Humans
  91. Mateen FJ, Nassar A, Bardia A, Jatoi A, Haddock MG, Buckner JC, Lachance DH. Spinal intradural extraosseous Ewing's sarcoma. Rare Tumors. 2011 Mar 30; 3(1):e7. PMID: 21464880.
    Citations: 3     
  92. Gill S, Loprinzi C, Kennecke H, Grothey A, Nelson G, Woods R, Speers C, Alberts SR, Bardia A, O'Connell MJ, Sargent DJ. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer. 2011 Sep 15; 117(18):4155-65. PMID: 21365628.
    Citations: 7     Fields:    Translation:HumansPHPublic Health
  93. Oxentenko AS, Bardia A, Vierkant RA, Wang AH, Anderson KE, Campbell PT, Sellers TA, Folsom AR, Cerhan JR, Limburg PJ. Body size and incident colorectal cancer: a prospective study of older women. Cancer Prev Res (Phila). 2010 Dec; 3(12):1608-20. PMID: 20719902.
    Citations: 21     Fields:    Translation:Humans
  94. Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, Cerhan JR. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 2011 Feb; 126(1):149-55. PMID: 20669045.
    Citations: 26     Fields:    Translation:Humans
  95. Bardia A, Stearns V. Personalized tamoxifen: a step closer but miles to go. Clin Cancer Res. 2010 Sep 01; 16(17):4308-10. PMID: 20651057.
    Citations:    Fields:    Translation:Humans
  96. Bardia A, Stearns V. Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy. Breast Cancer Res Treat. 2010 Apr; 120(2):437-9. PMID: 20162380.
    Citations: 3     Fields:    Translation:Humans
  97. Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Menon S, Thome S, Gill S, Sargent D. Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. Semin Oncol. 2010 Feb; 37(1):39-46. PMID: 20172363.
    Citations: 10     Fields:    Translation:Humans
  98. Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol. 2009 Aug; 9(4):419-26. PMID: 19574101.
    Citations: 22     Fields:    Translation:HumansAnimals
  99. Bardia A, Swanson EA, Thomas KG. 66-year-old woman with painless vesicular lesions. Mayo Clin Proc. 2009 Jul; 84(7):639-42. PMID: 19567718.
    Citations:    Fields:    Translation:Humans
  100. Bardia A, Novotny P, Sloan J, Barton D, Loprinzi C. Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause. 2009 May-Jun; 16(3):477-83. PMID: 19188850.
    Citations: 7     Fields:    Translation:Humans
  101. Bardia A, Greeno E, Miller R, Alberts S, Dozois E, Haddock M, Limburg P. Is a solitary inguinal lymph node metastasis from adenocarcinoma of the rectum really a metastasis? Colorectal Dis. 2010 Apr; 12(4):312-5. PMID: 19250258.
    Citations: 9     Fields:    Translation:Humans
  102. Bardia A, Vachon CM, Olson JE, Vierkant RA, Wang AH, Hartmann LC, Sellers TA, Cerhan JR. Relative weight at age 12 and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2008 Feb; 17(2):374-8. PMID: 18250344.
    Citations: 21     Fields:    Translation:Humans
  103. Bleicher J, Bhaskara A, Huyck T, Constantino S, Bardia A, Loprinzi CL, Silberstein PT. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials. J Support Oncol. 2008 Jan; 6(1):27-32. PMID: 18257398.
    Citations: 2     Fields:    Translation:Humans
  104. Bardia A, Tleyjeh IM, Cerhan JR, Sood AK, Limburg PJ, Erwin PJ, Montori VM. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc. 2008 Jan; 83(1):23-34. PMID: 18173999.
    Citations: 37     Fields:    Translation:Humans
  105. Bardia A, Holtan SG, Slezak JM, Thompson WG. Diagnosis of obesity by primary care physicians and impact on obesity management. Mayo Clin Proc. 2007 Aug; 82(8):927-32. PMID: 17673060.
    Citations: 27     Fields:    Translation:Humans
  106. Thompson S, Bardia A, Tan A, Barton DL, Kottschade L, Sloan JA, Christensen B, Smith D, Loprinzi CL. Levetiracetam for the treatment of hot flashes: a phase II study. Support Care Cancer. 2008 Jan; 16(1):75-82. PMID: 17598133.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  107. Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, Olson JE, Vachon CM, Cerhan JR. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 2007 Jun 06; 99(11):881-9. PMID: 17551148.
    Citations: 26     Fields:    Translation:Humans
  108. Sood A, Knudsen K, Sood R, Wahner-Roedler DL, Barnes SA, Bardia A, Bauer BA. Publication bias for CAM trials in the highest impact factor medicine journals is partly due to geographical bias. J Clin Epidemiol. 2007 Nov; 60(11):1123-6. PMID: 17938053.
    Citations: 8     Fields:    
  109. Bardia A, Nisly NL, Zimmerman MB, Gryzlak BM, Wallace RB. Use of herbs among adults based on evidence-based indications: findings from the National Health Interview Survey. Mayo Clin Proc. 2007 May; 82(5):561-6. PMID: 17493422.
    Citations: 23     Fields:    Translation:HumansAnimals
  110. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc. 2007 Apr; 82(4):490-513. PMID: 17418079.
    Citations: 32     Fields:    Translation:Humans
  111. Bardia A, Greeno E, Bauer BA. Dietary supplement usage by patients with cancer undergoing chemotherapy: does prognosis or cancer symptoms predict usage? J Support Oncol. 2007 Apr; 5(4):195-8. PMID: 17500507.
    Citations: 3     Fields:    Translation:Humans
  112. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007 Mar; 82(3):364-80. PMID: 17352373.
    Citations: 77     Fields:    Translation:Humans
  113. Thompson WG, Cook DA, Clark MM, Bardia A, Levine JA. Treatment of obesity. Mayo Clin Proc. 2007 Jan; 82(1):93-101; quiz 101-2. PMID: 17285790.
    Citations: 8     Fields:    Translation:Humans
  114. Bardia A, Thompson CA, Podratz KC, Okuno SH. Bizarre big belly ball: intraabdominal abscess mimicking stauffer syndrome secondary to uterine leiomyosarcoma. Eur J Gynaecol Oncol. 2007; 28(2):134-6. PMID: 17479677.
    Citations:    Fields:    Translation:Humans
  115. Bardia A, Hartmann LC, Vachon CM, Vierkant RA, Wang AH, Olson JE, Sellers TA, Cerhan JR. Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status. Arch Intern Med. 2006 Dec 11-25; 166(22):2478-83. PMID: 17159013.
    Citations: 20     Fields:    Translation:Humans
  116. Bardia A, Barton DL, Prokop LJ, Bauer BA, Moynihan TJ. Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. J Clin Oncol. 2006 Dec 01; 24(34):5457-64. PMID: 17135649.
    Citations: 31     Fields:    Translation:Humans
  117. Bardia A, Rao RD. Images in clinical medicine. Intratracheal melanoma metastases. N Engl J Med. 2006 Sep 28; 355(13):1357. PMID: 17005953.
    Citations:    Fields:    Translation:Humans
  118. Bardia A, Wahner-Roedler DL, Erwin PL, Sood A. Search strategies for retrieving complementary and alternative medicine clinical trials in oncology. Integr Cancer Ther. 2006 Sep; 5(3):202-5. PMID: 16880424.
    Citations: 4     Fields:    Translation:Humans
  119. Bardia A, Thompson S, Atherton PJ, Barton DL, Sloan JA, Kottschade LA, Christensen B, Collins M, Loprinzi CL. Pilot evaluation of aprepitant for the treatment of hot flashes. Support Cancer Ther. 2006 Jul 01; 3(4):240-6. PMID: 18632500.
    Citations: 2     
  120. Bardia A, Williamson EE, Bauer BA. Scarring moxibustion and religious scarification resulting in hepatitis C and hepatocellular carcinoma. Lancet. 2006 May 27; 367(9524):1790. PMID: 16731275.
    Citations: 1     Fields:    Translation:Humans
  121. Bardia A, Anand K. Sex ratio in India. Lancet. 2006 May 27; 367(9524):1727-8. PMID: 16731262.
    Citations:    Fields:    Translation:Humans
  122. Bardia A, Loprinzi CL, Goetz MP. Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series. J Clin Oncol. 2006 May 01; 24(13):e18-9. PMID: 16648492.
    Citations: 4     Fields:    Translation:Humans
  123. Bardia A, Pittelkow MR, Rao RD. Risk of multiple primary melanomas. JAMA. 2006 Apr 05; 295(13):1516. PMID: 16595755.
    Citations:    Fields:    Translation:Humans
  124. Bardia A, Stoikes N, Wilkinson NW. Mediastinal pancreatic pseudocyst with acute airway obstruction. J Gastrointest Surg. 2006 Jan; 10(1):146-50. PMID: 16368505.
    Citations: 6     Fields:    Translation:Humans
  125. Bajpai A, Bagga A, Hari P, Bardia A, Mantan M. Long-term outcome in children with primary distal renal tubular acidosis. Indian Pediatr. 2005 Apr; 42(4):321-8. PMID: 15876593.
    Citations: 8     Fields:    Translation:Humans
  126. Bajpai A, Bardia A, Mantan M, Hari P, Bagga A. Non-azotemic refractory rickets in Indian children. Indian Pediatr. 2005 Jan; 42(1):23-30. PMID: 15695854.
    Citations: 3     Fields:    Translation:Humans
  127. Bardia A, Paul E, Kapoor SK, Anand K. Declining sex ratio: role of society, technology and government regulation in Faridabad district, Haryana. Natl Med J India. 2004 Jul-Aug; 17(4):207-11. PMID: 15372767.
    Citations: 4     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Bardia's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (396)
Explore
_
Co-Authors (109)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.